119 results on '"Hasle, Henrik"'
Search Results
2. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
3. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome
4. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
5. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression
6. HNA specificity and association to HLA-DRB1 and -DQB1 in patients with autoimmune neutropenia of early childhood
7. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
8. Inflammatory Biomarkers Can Differentiate Acute Lymphoblastic Leukemia with Arthropathy from Juvenile Idiopathic Arthritis Better Than Standard Blood Tests
9. European standard clinical practice – Key issues for the medical care of individuals with familial leukemia
10. Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration
11. Psychiatric disorders in childhood cancer survivors in Denmark, Finland, and Sweden: a register-based cohort study from the SALiCCS research programme
12. Childhood cancer: Survival, treatment modalities, late effects and improvements over time
13. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia
14. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group
15. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
16. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial
17. P37 - JMML WITH NRAS MUTATION IN ELANE ASSOCIATED SEVERE CONGENITAL NEUTROPENIA
18. P28 - RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
19. P27 - MYELODYSPLASIA-RELATED CYTOGENETIC ABNORMALITES IN CHILDHOOD ACUTE MYELOID LEUKEMIA – A 20-YEAR I-BFM- AML COLLABORATIVE DATABASE STUDY
20. P6 - NPM1 MUTATIONS IN CHILDREN WITH MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
21. OC 20 - GENOTYPE/PHENOTYPE ASSOCIATIONS IN 174 INDIVIDUALS WITH GERMLINE GATA2 MUTATIONS
22. OC 15 - WHAT CAN WE DEDUCE FROM MOLECULAR CLASSIFICATION OF MYELOID NEOPLASIA FOR THERAPY IN PEDIATRICS?
23. Long-term risk of renal and urinary tract diseases in childhood cancer survivors: A population-based cohort study
24. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents
25. LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia
26. Classification of treatment-related mortality in children with cancer: a systematic assessment
27. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study
28. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study
29. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group
30. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype
31. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
32. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
33. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML
34. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study
35. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome
36. The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study
37. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2
38. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias
39. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
40. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
41. Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
42. Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR)
43. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder
44. Minimal residual core binding factor AMLs by real time quantitative PCR—Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse
45. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
46. Association between Fc-Gamma Receptor Polymorphisms and Autoimmune Neutropenia in Early Childhood in Danish Patients
47. Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
48. UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
49. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7
50. Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.